[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639878":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":11,"studyPopulation":11,"armGroups":30,"interventions":43,"overallOfficials":51,"centralContacts":55,"locations":63,"responsibleParty":77,"collaborators":11,"id":79,"slug":11,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Frequency of Adverse Events",null,"Up to 12 months",[14,17],{"measure":15,"description":11,"timeFrame":16},"Concentrations of ALN-6222 in Plasma","Predose and up to 3 days postdose",{"measure":18,"description":11,"timeFrame":19},"Change from Baseline Protein Markers in Plasma","Predose and up to 12 months postdose",{"allocation":21,"interventionModel":22,"interventionModelDescription":11,"primaryPurpose":23,"observationalModel":11,"timePerspective":11,"maskingInfo":24},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":25,"maskingDescription":11,"whoMasked":26},"TRIPLE",[27,28,29],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[31,37],{"label":32,"type":33,"description":34,"interventionNames":35},"ALN-6222","EXPERIMENTAL","Participants will be administered a single dose of ALN-6222.",[36],"Drug: ALN-6222",{"label":38,"type":39,"description":40,"interventionNames":41},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[42],"Drug: Placebo",[44,48],{"type":45,"name":32,"description":46,"armGroupLabels":47,"otherNames":11},"DRUG","ALN-6222 will be administered subcutaneously (SC).",[32],{"type":45,"name":38,"description":49,"armGroupLabels":50,"otherNames":11},"Placebo will be administered SC.",[38],[52],{"name":53,"affiliation":5,"role":54},"Medical Director","STUDY_DIRECTOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":57,"role":58,"phone":62,"phoneExt":11,"email":60},"1-877-256-9526",[64],{"facility":65,"status":66,"city":67,"state":11,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":11},"Clinical Trial Site","RECRUITING","Mount Royal","H3P 3P1","Canada","CA",{"type":72,"coordinates":73},"Point",[74,75],-73.64918,45.51675,{"lat":75,"lon":74},{"type":78,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100639878",false,"NCT07624071","A Study to Evaluate ALN-6222 in Participants With Obesity","A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity","Inclusion Criteria -\n\n* Is an adult patient with a body mass index ≥30 kg\u002Fm\\^2 to \\\u003C40 kg\u002Fm\\^2\n* Has a hemoglobin A1c \\\u003C6.5%\n\nExclusion Criteria -\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>1.5 times the upper limit of normal (ULN)\n* Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection\n* Has an estimated glomerular filtration (eGFR) of \\\u003C60 mL\u002Fmin\u002F1.73m\\^2 at screening\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years","65 Years",{"count":89,"type":90},88,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.",[96],"Obesity",[98],"siRNA, RNAi therapeutic","2026-06-25",{"date":101,"type":102},"2026-06-29","ACTUAL",{"date":104,"type":102},"2026-06-04",{"date":106,"type":90},"2027-12-14",{"name":5,"class":6},1]